Literature DB >> 7624358

Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.

A A Patchett1, R P Nargund, J R Tata, M H Chen, K J Barakat, D B Johnston, K Cheng, W W Chan, B Butler, G Hickey.   

Abstract

A potent, orally active growth hormone (GH) secretagogue L-163,191 belonging to a recently synthesized structural class has been characterized. L-163,191 releases GH from rat pituitary cells in culture with EC50 = 1.3 +/- 0.09 nM and is mechanistically indistinguishable from the GH-releasing peptide GHRP-6 and the prototypical nonpeptide GH secretagogue L-692,429 but clearly distinguishable from the natural GH secretagogue, GH-releasing hormone. L-163,191 elevates GH in dogs after oral doses as low as 0.125 mg/kg and was shown to be specific in its release of GH without significant effect on plasma levels of aldosterone, luteinizing hormone, thyroxine, and prolactin after oral administration of 1 mg/kg. Only modest increases in cortisol were observed. Based on these properties, L-163,191 has been selected for clinical studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7624358      PMCID: PMC41459          DOI: 10.1073/pnas.92.15.7001

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles.

Authors:  G Hickey; T Jacks; F Judith; J Taylor; W R Schoen; D Krupa; P Cunningham; J Clark; R G Smith
Journal:  Endocrinology       Date:  1994-02       Impact factor: 4.736

2.  On a peptidomimetic growth hormone-releasing peptide.

Authors:  C Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  1994-10       Impact factor: 5.958

3.  Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.

Authors:  J A Aloi; B J Gertz; M L Hartman; W C Huhn; S S Pezzoli; J M Wittreich; D A Krupa; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1994-10       Impact factor: 5.958

4.  Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.

Authors:  E Ghigo; E Arvat; L Gianotti; B P Imbimbo; V Lenaerts; R Deghenghi; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

5.  GH releasing peptides--structure and kinetics.

Authors:  C Y Bowers
Journal:  J Pediatr Endocrinol       Date:  1993 Jan-Mar

6.  Central actions of peptide and non-peptide growth hormone secretagogues in the rat.

Authors:  S L Dickson; G Leng; R E Dyball; R G Smith
Journal:  Neuroendocrinology       Date:  1995-01       Impact factor: 4.914

7.  Untoward events in patients treated with growth hormone in the USA.

Authors:  R L Hintz
Journal:  Horm Res       Date:  1992

8.  Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin).

Authors:  Z Laron; J Frenkel; I Gil-Ad; B Klinger; E Lubin; P Wuthrich; F Boutignon; V Lengerts; R Deghenghi
Journal:  Clin Endocrinol (Oxf)       Date:  1994-10       Impact factor: 3.478

9.  Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.

Authors:  B J Gertz; J S Barrett; R Eisenhandler; D A Krupa; J M Wittreich; J R Seibold; S H Schneider
Journal:  J Clin Endocrinol Metab       Date:  1993-11       Impact factor: 5.958

10.  A nonpeptidyl growth hormone secretagogue.

Authors:  R G Smith; K Cheng; W R Schoen; S S Pong; G Hickey; T Jacks; B Butler; W W Chan; L Y Chaung; F Judith
Journal:  Science       Date:  1993-06-11       Impact factor: 47.728

View more
  42 in total

Review 1.  Exploring privileged structures: the combinatorial synthesis of cyclic peptides.

Authors:  Douglas A Horton; Gregory T Bourne; Mark L Smythe
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

Review 2.  Exploring privileged structures: the combinatorial synthesis of cyclic peptides.

Authors:  Douglas A Horton; Gregory T Bourne; Mark L Smythe
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

3.  Agonism, Antagonism, and Inverse Agonism Bias at the Ghrelin Receptor Signaling.

Authors:  Céline M'Kadmi; Jean-Philippe Leyris; Lauriane Onfroy; Céline Galés; Aude Saulière; Didier Gagne; Marjorie Damian; Sophie Mary; Mathieu Maingot; Séverine Denoyelle; Pascal Verdié; Jean-Alain Fehrentz; Jean Martinez; Jean-Louis Banères; Jacky Marie
Journal:  J Biol Chem       Date:  2015-09-11       Impact factor: 5.157

4.  Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism.

Authors:  Andras Kern; Rosie Albarran-Zeckler; Heidi E Walsh; Roy G Smith
Journal:  Neuron       Date:  2012-01-26       Impact factor: 17.173

Review 5.  The Safety and Efficacy of Growth Hormone Secretagogues.

Authors:  John T Sigalos; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2017-04-08

Review 6.  Growth hormone secretagogues as diagnostic tools in disease states.

Authors:  R Baldelli; X L Otero; J P Camiña; O Gualillo; V Popovic; C Dieguez; F F Casanueva
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

7.  Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue.

Authors:  L C Pan; P A Carpino; B A Lefker; J A Ragan; S M Toler; J C Pettersen; D O Nettleton; O Ng; C M Pirie; K Chidsey-Frink; B Lu; D F Nickerson; D A Tess; M A Mullins; D B MacLean; P A DaSilva-Jardine; D D Thompson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

8.  Hexarelin: a multi-receptor peptide.

Authors:  R Deghenghi
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

9.  Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.

Authors:  L Yang; S C Berk; S P Rohrer; R T Mosley; L Guo; D J Underwood; B H Arison; E T Birzin; E C Hayes; S W Mitra; R M Parmar; K Cheng; T J Wu; B S Butler; F Foor; A Pasternak; Y Pan; M Silva; R M Freidinger; R G Smith; K Chapman; J M Schaeffer; A A Patchett
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

10.  Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor.

Authors:  Yuxiang Sun; Pei Wang; Hui Zheng; Roy G Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.